BioLineRx (BLRX) Operating Leases (2018 - 2026)

BioLineRx's Operating Leases history runs 8 years deep, the most recent figure standing at $1.2 million for Q4 2025.

• In Q4 2025, Operating Leases fell 24.45% year-over-year to $1.2 million; the TTM figure through Dec 2025 stood at $1.2 million (down 24.45% YoY), while the FY2025 annual figure was $1.2 million, down 24.45% from the prior year.
• Operating Leases for Q4 2025 stood at $1.2 million, up from $998000.0 in the prior quarter.
• The five-year high for Operating Leases was $2.2 million in Q4 2022, with the low at $998000.0 in Q2 2025.
• The 5-year median for Operating Leases is $1.6 million (2023), against an average of $1.6 million.
• The sharpest annual moves came in 2022 and 2025: Operating Leases advanced 13.83% in 2022, then fell 24.45% in 2025.
• BioLineRx's Operating Leases stood at $1.9 million in 2021, then rose by 13.83% to $2.2 million in 2022, then declined by 15.68% to $1.8 million in 2023, then slipped by 11.83% to $1.6 million in 2024, then dropped by 24.45% to $1.2 million in 2025.
• Business Quant data shows BLRX's Operating Leases at $1.2 million in Q4 2025, $998000.0 in Q2 2025, and $1.6 million in Q4 2024.